Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02501811
Other study ID # HSC-SPH-15-0413
Secondary ID 5UM1HL087318
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2015
Est. completion date July 22, 2020

Study information

Verified date March 2021
Source The University of Texas Health Science Center, Houston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination (Combo), compared to placebo (cell-free Plasmalyte-A medium) as well as each other, administered by transendocardial injection in subjects with ischemic cardiomyopathy.


Description:

This is a randomized, placebo-controlled clinical trial designed to evaluate the feasibility, safety, and effect of Combo, MSCs alone, and c-kit+ cells alone compared with placebo as well as each other in subjects with heart failure of ischemic etiology. Following a successful lead-in phase, a total of one hundred forty-four (144) subjects will be randomized (1:1:1:1) to receive Combo, MSCs, c-kit+ cells, or placebo. After randomization, baseline imaging, relevant harvest procedures, and study product injection, subjects will be followed up at 1 day, 1 week, 1 month, 3 months, 6 months and 12 months post study product injection. All subjects will receive study product injection (cells or placebo) using the NOGA® XP Mapping and Navigation System. Subjects will have delayed-enhanced magnetic resonance imaging (DEMRI) scans to assess scar size and LV function and structure at baseline and at 6 and 12 months post study product administration. All endpoints will be assessed at the 6 and 12 month visits which will occur 180 ±30 days and 365 ±30 days respectively from the day of study product injection (Day 0). For the purpose of the endpoint analysis and safety evaluations, the Investigators will utilize an "intention-to-treat" study population, however an as treated analysis will also be conducted.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date July 22, 2020
Est. primary completion date June 25, 2020
Accepts healthy volunteers No
Gender All
Age group 21 Years to 79 Years
Eligibility Inclusion Criteria: 1. Be = 21 and <80 years of age 2. Have documented coronary artery disease (CAD) with evidence of myocardial injury, LV dysfunction, and clinical evidence of HF 3. Have a "detectable" area of myocardial injury defined as = 5% LV involvement (infarct volume) and any subendocardial involvement by cMRI 4. Have an EF = 40% by cMRI 5. Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for = 1 month prior to consent. For beta-blockade "stable" is defined as no greater than a 50% reduction in dose or no more than a 100% increase in dose. 6. Be a candidate for cardiac catheterization 7. Have NYHA class I, II, or III heart failure symptoms 8. If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 hours prior to injection Exclusion Criteria: 1. Indication for standard-of-care surgery (including valve surgery, placement of left-ventricular assist device, or imminent heart transplantation), coronary artery bypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI) for the treatment of ischemic and/or valvular heart disease. Subjects who require or undergo PCI should undergo these procedures a minimum of 3 months in advance of randomization. Subjects who require or undergo CABG should undergo these procedures a minimum of 4 months in advance of randomization. In addition, subjects who develop a need for revascularization following enrollment should undergo revascularization without delay. Indication for imminent heart transplantation is defined as a high likelihood of transplant prior to collection of the 12 month study endpoint. Candidates cannot be UNOS status 1A or 1B, and they must have documented low probability of being transplanted 2. Valvular heart disease including 1) mechanical or bioprosthetic heart valve; or 2) severe (any valve) insufficiency/regurgitation within 12 months of consent 3. Aortic stenosis with valve area = 1.5 cm2 4. History of ischemic or hemorrhagic stroke within 90 days of consent 5. History of a left ventricular remodeling surgical procedure utilizing prosthetic material 6. Presence of a pacemaker and/or implantable cardioverter-defibrillator (ICD) generator with any of the following limitations/conditions: - manufactured before the year 2000 - leads implanted < 6 weeks prior to consent - non-transvenous epicardial, or abandoned leads - subcutaneous ICDs - leadless pacemakers - any other condition that, in the judgment of device-trained staff, would deem an MRI contraindicated 7. Pacemaker-dependence with an ICD (Note: pacemaker-dependent candidates without an ICD are not excluded) 8. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent 9. Other MRI contraindications (e.g. patient body habitus incompatible with MRI) 10. An appropriate ICD firing or anti-tachycardia pacing (ATP) for ventricular fibrillation or ventricular tachycardia within 30 days of consent 11. Ventricular tachycardia = 20 consecutive beats without an ICD within 3 months of consent, or symptomatic Mobitz II or higher degree atrioventricular block without a functioning pacemaker within 3 months of consent 12. Presence of LV thrombus 13. Evidence of active myocarditis 14. Baseline maximal oxygen consumption (VO2 max) greater than 75% of age and gender based predictive values 15. Baseline eGFR <35 ml/min/1.73m2 16. Blood glucose levels (HbA1c) >10% 17. Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet count < 100,000/ul 18. Liver dysfunction evidenced by enzymes (AST and ALT) ? 3 times the upper limit of normal (ULN) 19. Coagulopathy (INR = 1.3) not due to a reversible cause (e.g., warfarin and/or Factor Xa inhibitors). Subjects who cannot be withdrawn from anticoagulation will be excluded. 20. HIV and/or active hepatitis B virus (HBV) or hepatitis C virus (HCV) 21. Allergy to radiographic contrast material that cannot adequately be managed by premedication 22. Known history of anaphylactic reaction to penicillin or streptomycin 23. Received gene or cell-based therapy from any source within the previous 12 months 24. History of malignancy within 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), excluding basal cell carcinoma and cervical carcinoma in situ which have been definitively treated 25. Condition that limits lifespan to < 1 year 26. History of drug abuse (illegal "street" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (= 5 drinks/day for ? 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months 27. Participation in an investigational therapeutic or device trial within 30 days of consent 28. Cognitive or language barriers that prohibit obtaining informed consent or any study elements 29. Pregnancy or lactation or plans to become pregnant in the next 12 months 30. Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Mesenchymal Stem Cells (MSC)
15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
c-kit+ cells
15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Placebo (Plasmalyte A)
15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Locations

Country Name City State
United States University of Florida-Department of Medicine Gainesville Florida
United States Texas Heart Institute Houston Texas
United States Indiana Center for Vascular Biology and Medicine Indianapolis Indiana
United States University of Louisville Louisville Kentucky
United States University of Miami-Interdisciplinary Stem Cell Institute Miami Florida
United States Minneapolis Heart Institute Foundation Minneapolis Minnesota
United States Stanford University School of Medicine (Falk Cardiovascular Research Center) Stanford California

Sponsors (2)

Lead Sponsor Collaborator
The University of Texas Health Science Center, Houston National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Bolli R, Hare JM, March KL, Pepine CJ, Willerson JT, Perin EC, Yang PC, Henry TD, Traverse JH, Mitrani RD, Khan A, Hernandez-Schulman I, Taylor DA, DiFede DL, Lima JAC, Chugh A, Loughran J, Vojvodic RW, Sayre SL, Bettencourt J, Cohen M, Moyé L, Ebert RF, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit(+) Cardiac Stem Cells As Regenerative Therapy for Heart Failure). Circ Res. 2018 Jun 8;122(12):1703-1715. doi: 10.1161/CIRCRESAHA.118.312978. Epub 2018 Apr 27. — View Citation

Hare JM, Bolli R, Cooke JP, Gordon DJ, Henry TD, Perin EC, March KL, Murphy MP, Pepine CJ, Simari RD, Skarlatos SI, Traverse JH, Willerson JT, Szady AD, Taylor DA, Vojvodic RW, Yang PC, Moyé LA; Cardiovascular Cell Therapy Research Network. Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation. 2013 Apr 16;127(15):1630-5. doi: 10.1161/CIRCULATIONAHA.112.000779. — View Citation

Nazarian S, Halperin HR. How to perform magnetic resonance imaging on patients with implantable cardiac arrhythmia devices. Heart Rhythm. 2009 Jan;6(1):138-43. doi: 10.1016/j.hrthm.2008.10.021. Epub 2008 Oct 22. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Subjects With Events Between Randomization and Study Product Injection (SPI) That Preclude the Receipt of Product Number and percent of subjects with events between randomization and study product injection (SPI) that preclude the subject from receiving product. Reasons include those who did not undergo harvest (n=6; death, subject withdraw, subject changed mind) and those who did not undergo SPI (n=9; death, LVAD placement, episodes of ventricular tachycardia, and cancelled procedures) Randomization to SPI, an average of 14 weeks
Other Subjects Who Have a Failed Bone Marrow Aspiration Procedure Number and percent of subjects who do not successfully undergo bone marrow aspiration During bone marrow aspiration procedure
Other Subjects Who Have a Failed Endomyocardial Biopsy Procedure Number and percent of subjects who do not successfully undergo endomyocardial biopsy procedure. Note only participants who were assigned to MSC+CPC or to CPC groups had endomyocardial biopsy procedures attempted. During endomyocardial biopsy procedure
Other Subject MSC Products Which Failed Release Criteria Number and percent of subjects who have MSC products which failed release criteria Harvest to Study Product Injection Procedure
Other Subject CPC Products Which Failed Release Criteria Number and percent of subjects who have CPC products which failed release criteria Harvest to Study Project Injection procedure
Other Subjects Who Receive Less Than 15 Injections During SPI Number and percent of subjects who received less than 15 injections during SPI During SPI procedure
Other Subjects Who Have at Least One Cardiac MRI Endpoint Measure That is Uninterpretable Number and percent of subjects who have at least one cardiac MRI endpoint measure that is uninterpretable due to issues related to the device, including, but not limited to, inability to undergo the procedure Baseline to 12 months
Primary Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Change in left ventricular ejection fraction as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Global Strain (HARP MRI) Change in global circumferential strain as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Regional Strain (HARP MRI) Change in regional longitudinal strain as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) Change in left ventricular end diastolic volume index as measured via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Change in left ventricular end systolic volume index as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Left Ventricular Sphericity Index Change in left ventricular sphericity as assessed via cardiac MRI. Sphericity index is the ratio of the long and short axis measurements of the left ventricle. Baseline to 6 months
Primary Change From Baseline in Scar Size Percent (DEMRI) Change in scar size percent as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Scar Tissue Mass (DEMRI) Change in scar tissue mass as assessed via cardiac MRI Baseline to 6 months
Primary Change From Baseline in Maximal Oxygen Consumption (Peak VO2) Change in maximal oxygen consumption (peak V02) as assessed via treadmill Baseline to 6 months
Primary Change From Baseline in Exercise Tolerance (Six Minute Walk Test) Change in distance walked (in meters) as measured by the 6 minute walk test. Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis. Baseline to 6 months
Primary Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score Change in the quality of life summary score as measured by the Minnesota Living with Heart Failure Questionnaire. Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes. Baseline to 6 months
Primary Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Change in N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) as measured via laboratory blood draw Baseline to 6 months
Primary Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Global Strain (HARP MRI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Regional Strain (HARP MRI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, 12 months)
Primary Change From Baseline in Left Ventricular Sphericity Index-Trajectory Sphericity index is the ratio of the long and short axis measurements of the left ventricle. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Scar Size Percent (DEMRI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory Two walk tests were completed at each endpoint visit (separated by 30 minutes). The average distance of the two walk tests was used for analysis. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory Minimum and maximum scores for the scale are 0 and 105 respectively. Lower scores indicative of better outcomes. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The 2nd and 3rd set of results represent differences for varying slopes from the interaction model. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory Log transformation used. The change in this measure over time is assessed using a repeated measures linear regression model of trajectory (change over time). The first set of results reflects the model within each arm and represents change per 6 months within that treatment arm. The second set of results reflects an overall model with all patients and the results represent the change per 6 months irrespective of treatment arm. Assessed as a trajectory (baseline, 6 months, and 12 months)
Primary Participants With Major Adverse Cardiac Events (MACE) Number of participants with adjudicated events including death, hospitalization for worsening heart failure, and/or other exacerbation of heart failure (non-hospitalization). Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
Primary Participants Experiencing Other Significant Clinical Events Number of participants experiencing other significant adjudicated clinical events including: non-fatal stroke, non-fatal MI, coronary artery revascularization, ventricular tachycardia/fibrillation, and pericardial tamponade Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
Primary Cumulative Days Alive and Out of Hospital for Heart Failure Days alive and out of hospital during the study evaluation period. Subjects were allotted a visit window extending 30 days past their anticipated 12-month visit. Some participants had extended 12-month visit windows due to the COVID-19 pandemic. Baseline to End of 12 Month Visit Window, an average of 395 days following study product injection
See also
  Status Clinical Trial Phase
Terminated NCT04066738 - Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Enrolling by invitation NCT02930265 - Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy N/A
Completed NCT01215253 - Ranolazine Implantable Cardioverter-Defibrillator Trial Phase 3
Completed NCT04508608 - Scintigraphic Evaluation of Contractile and Coronary Reserve in Patients With Ischemic Cardiomyopathy
Recruiting NCT05888662 - Endo-epicardial vs Endocardial-only Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy (EPIC-VT) N/A
Completed NCT03857906 - Evaluation of Prophylactic Use of a Preoperative IABP in High-Risk Coronary Artery Bypass Graft Surgery
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Not yet recruiting NCT01946048 - Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy Phase 1
Terminated NCT01759212 - Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure. Phase 2/Phase 3
Not yet recruiting NCT01447069 - Use of Beta-agonists in Stable Severe Congestive Heart Failure N/A
Recruiting NCT00972114 - CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy Phase 1/Phase 2
Completed NCT00896142 - Optima Coronary Artery Disease (CAD) (Optimal Mechanical Evaluation) N/A
Recruiting NCT01076660 - Left Ventricular Structural Predictors of Sudden Cardiac Death
Completed NCT00305240 - MASTER I - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Completed NCT00305214 - MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients N/A
Active, not recruiting NCT00962364 - Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease
Recruiting NCT05769036 - Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients N/A
Completed NCT03862339 - The SoundScar Study The SOUNDSCAR Study
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A